In the race to improve healthcare, Bush likes a smartwatch’s chances

Former Florida Governor Jeb Bush has not yet declared himself a presidential candidate, but the likely contender has tipped his hat to a piece of technology that, by all appearances, inspires his drive to undo the Affordable Care Act.

During a stop in Arizona last week, Bush praised the potential of his Apple Watch.

"On this device in five years will be applications that will allow me to manage my healthcare in ways that five years ago were not even possible,” he said. “Because of my blood sugar … I'll get a double beep saying, ‘You just ate a butterscotch sundae. You went way over the top, you’re a diabetic, you can't do that.’ We’ll be able to guide our own healthcare decisions in a way that will make us healthy.”

Bush also reiterated his belief that getting healthcare right means stripping involvement from the federal government and sending it to the states:

“I think we should repeal Obamacare if given the opportunity and replace it with a consumer-directed model where people are engaged in making healthcare decisions for themselves and where they’re given the tools to do so.”

It didn’t take long for a political leader from the other side of the aisle to issue a direct rebuttal.

“@jebbush I had cancer,” tweeted Debbie Wasserman Schultz, chair of the Democratic National Committee, the very next day. “There’s no app for that.”  

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.